MobiHealth News July 19, 2024
The company will use the funds to accelerate its growth, expand the use of its models for different conditions and open an office in Cambridge.
Israeli startup CytoReason, maker of a computation model to map and compare treatments, announced it secured $80 million in funding.
Pfizer, OurCrowd, NVIDIA and Thermo Fisher Scientific participated in the round.
WHAT IT DOES
CytoReason offers life sciences companies AI-enabled tools to gather data-driven and molecular-level insights to improve phase 2 success in clinical trials and optimize research and development.
The company’s model provides insights into datasets and literature, cell states, what drives disease progression over time, disease variation between patients, cell composition, cell interactions based on biological features in tissues and...
Today's Sponsors
Today's Sponsor